These findings suggest that CD4+Notch2+Foxp3lo T cells may serve as novel mediators of the transition from the dysfunctional phenotype to immune regulatory conditions through Notch2 expression, potentially representing a new therapeutic target for autoimmune diseases. This evidence concerns the gene CD4 and autoimmune disease.